Global Congestive Heart Failure (CHF) Treatment Devices Market is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 8.5% during forecast period.
Global Congestive Heart Failure (CHF) Treatment Devices Market Overview:
Congestive heart failure (CHF) is a disorder in which the heart muscles’ capacity to pump enough blood is impaired. Shortness of breath, exhaustion, and leg swelling are all symptoms of this illness. As a result, it’s critical to control heart failure with the help of numerous devices available on the market, such as defibrillators and pacemakers.
Global Congestive Heart Failure (CHF) Treatment Devices Market Dynamics:
Rising prevalence of cardiac disorders is the major factor contributing to the market growth.
The failure of the ventricles to pump a sufficient volume of blood to the bodily organs marks the beginnings of CHF. This causes fluid to accumulate in the lungs, abdomen, liver, and lower body. Pacemakers, cardiac resynchronization treatment (CRT), implanted cardioverter defibrillators (ICDs), and ventricular assist devices are among the technologies used to treat CHF. The growing frequency of cardiovascular disorders, technological improvements, and the rising number of cardiovascular surgeries are driving the market for congestive heart failure (CHF) therapy devices.
Other important factors linked to the development of CVDs include sedentary lifestyles, junk food consumption, and mental stress. According to the World Health Organization, cardiovascular disease is the leading cause of death worldwide in 2019, claiming the lives of an estimated 17.9 million people each year. As a result, the large target group has a positive impact on the treatment of congestive heart failure. Globally, the growing geriatric population is leading to an increase in CVD cases.
To increase market share, market players are focused on new growth strategies such as product launches, developments, mergers, and acquisitions. For example, Abbott Laboratories’ HeartMate 3 Left Ventricular Assist Device (LVAD) was approved by the US Food and Drug Administration (FDA) in October 2018 for the treatment of heart failure. In developing markets, there is likely to be a large unmet treatment need for congestive heart failure. High equipment costs and unfavourable reimbursement rules are two concerns that could stymie the congestive heart failure treatment market’s revenue growth.
The report has profiled sixteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.
Global Congestive Heart Failure (CHF) Treatment Devices Market Segment Analysis:
The Global Congestive Heart Failure (CHF) Treatment Devices Market is segmented on the basis of Product and End-Users.
Based on Product, the Implantable pacemakers segment is expected to account for significant market share XX% by 2026. An implantable pacemaker is a device that regulates cardiac rhythm using electrical impulses. An internal pacemaker has electrodes that are implanted in the heart and electronic circuitry and a power supply that is inserted within the body. According to a study published in the Journal of Arrhythmia in July 2020 by Ana C Gonzales-Luna et al., the COVID-19 pandemic resulted in a 73% reduction in pacemaker implants and a 78% reduction in de-novo pacemaker implants in patients diagnosed with complete or high-grade atrioventricular block, regardless of the aetiology. The growth of the implantable pacemakers segment is being fuelled by an increase in cardiovascular patients, as well as an increase in the geriatric population, reimbursement coverage, and technological advancements such as exclusive algorithms that accurately detect and reduce the risk of atrial fibrillation.
The Implantable Cardioverter Defibrillators segment is expected to grow at a significant CAGR of XX% throughout the forecast period. Implantable Cardioverter Defibrillators (ICDs) have a sizable market share thanks to their capacity to perform three main functions: defibrillation, cardioversion, and cardiac pacing. In 2019, the ICD category, which is divided into two types: transvenous and subcutaneous, had a sizable market share.
Global Congestive Heart Failure (CHF) Treatment Devices Market
To know about the Research Methodology :- Request Free Sample Report
Global Congestive Heart Failure (CHF) Treatment Devices Market Regional Insights:
Global Congestive Heart Failure (CHF) Treatment Devices Market
North America is expected to dominate the global market during forecast years.
Increased demand for congestive heart failure (CHF) therapy, rising prevalence of target illnesses, high healthcare spending, and increased population awareness about treatment device availability are some of the reasons driving market growth in the North American area. COVID-19 individuals with an underlying heart problem are still more likely to become critically unwell, according to the Centres for Disease Control and Prevention (CDC). In addition, supportive illness awareness activities are expected to assist the market for cardiovascular devices in the North American area. Mexico, for example, joined the HEARTS project in 2020 to improve primary health care for cardiovascular illnesses. As a result of the aforementioned factors, the market in North America is likely to rise at a rapid pace over the forecast years.
The report also helps in understanding Global Congestive Heart Failure (CHF) Treatment Devices Market dynamics, structure by analyzing the market segments and project the Global Congestive Heart Failure (CHF) Treatment Devices Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Congestive Heart Failure (CHF) Treatment Devices Market make the report investor’s guide.
Global Congestive Heart Failure (CHF) Treatment Devices Market, Key Development:
• Teleflex Inc. acquired the acquisition of Z-Medica LLC, a prominent maker of hemostatic products, in February 2021.
• Abbott Laboratories announced in December 2020 that the United States Food and Drug Administration (FDA) had authorised amended labelling for its HeartMate 3 heart pump for use in young patients with advanced refractory left ventricular heart failure.
Global Congestive Heart Failure (CHF) Treatment Devices Market Scope: Inquire before buying
Global Congestive Heart Failure (CHF) Treatment Devices Market
Global Congestive Heart Failure (CHF) Treatment Devices Market, by Region:
• North America
• Europe
• South America
• MEA
• APAC
Global Congestive Heart Failure (CHF) Treatment Devices Market, Key players:
• Boston Scientific Corporation
• Medtronic PLC
• Abiomed, Inc.
• HeartWare International, Inc.
• Jarvik Heart, Inc.
• LivaNova PLC
• ReliantHeart Inc.
• Biotronik SE & Co., KG
• St. Jude Medical
• Berlin Heart GmbH
• Teleflex, Inc.
• Abbott
• Edwards Lifesciences Corporation
• Johnson & Johnson Services, Inc
• MicroPort Scientific Corporation
• Mayo Foundation
